Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Whitlock

Showing results (251-260 of 272) with videos related to

Pageof 28
Sort By:
Journal of Medicinal Chemistry|November 17, 2015
Novel Amino-pyrazole Ureas with Potent In Vitro and In Vivo Antileishmanial ActivityCharles E Mowbray, Stéphanie Braillard, William Speed, et al.
Leukemia|February 26, 2020
Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemiaFranco Locatelli, James A Whitlock, Christina Peters, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2023
Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First RelapseLaura E Hogan, Patrick A Brown, Lingyun Ji, et al.
Journal of Medicinal Chemistry|December 17, 2016
Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and SkinPeter Jones, R Ian Storer, Yogesh A Sabnis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2019
A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation-Positive Solid TumorsMark W Kieran, Birgit Geoerger, Ira J Dunkel, et al.
Haematologica|February 3, 2022
Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001)Sarah K Tasian, Lewis B Silverman, James A Whitlock, et al.
Cancer Medicine|February 24, 2024
Access to innovative therapies in pediatric oncology: Report of the nationwide experience in CanadaSandra Judd, Gabriel Revon-Riviere, Stephanie A Grover, et al.
Journal of Medicinal Chemistry|October 29, 2021
DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral LeishmaniasisCharles E Mowbray, Stéphanie Braillard, Paul A Glossop, et al.
Nature Medicine|July 17, 2025
Clinical utility of targeted RNA sequencing in cancer molecular diagnosticsRobert Siddaway, Aida I Glembocki, Anthony Arnoldo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2016
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic LeukemiaArend von Stackelberg, Franco Locatelli, Gerhard Zugmaier, et al.
Pageof 28

Showing results (251-260 of 272) with videos related to

Sort By:
Pageof 28
Journal of Medicinal Chemistry|November 17, 2015
Novel Amino-pyrazole Ureas with Potent In Vitro and In Vivo Antileishmanial ActivityCharles E Mowbray, Stéphanie Braillard, William Speed, et al.
Leukemia|February 26, 2020
Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemiaFranco Locatelli, James A Whitlock, Christina Peters, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2023
Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First RelapseLaura E Hogan, Patrick A Brown, Lingyun Ji, et al.
Journal of Medicinal Chemistry|December 17, 2016
Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and SkinPeter Jones, R Ian Storer, Yogesh A Sabnis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2019
A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation-Positive Solid TumorsMark W Kieran, Birgit Geoerger, Ira J Dunkel, et al.
Haematologica|February 3, 2022
Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001)Sarah K Tasian, Lewis B Silverman, James A Whitlock, et al.
Cancer Medicine|February 24, 2024
Access to innovative therapies in pediatric oncology: Report of the nationwide experience in CanadaSandra Judd, Gabriel Revon-Riviere, Stephanie A Grover, et al.
Journal of Medicinal Chemistry|October 29, 2021
DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral LeishmaniasisCharles E Mowbray, Stéphanie Braillard, Paul A Glossop, et al.
Nature Medicine|July 17, 2025
Clinical utility of targeted RNA sequencing in cancer molecular diagnosticsRobert Siddaway, Aida I Glembocki, Anthony Arnoldo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2016
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic LeukemiaArend von Stackelberg, Franco Locatelli, Gerhard Zugmaier, et al.
Pageof 28